Application no. and date | 18730908.3 (espacenet) (Federated) (European Patent Register), 20180524 | Patent/reg. no. and date | DK/EP 3630164, 20230823 | Publication date | 20200408 | Priority no. and date | US 201762513556 P, 20170601 | EP pub. no. and date |
EP 3630164 20200408 | Effective date | | Applicant/owner | Eli Lilly and Company, Lilly Corporate Center
Indianapolis, IN 46285, US | Applicant ref. no. | V463159DK00 | Inventor | BOTROS, Fady Talaat, c/o Eli Lilly and Company P.O. Box 6288
Indianapolis, Indiana 46206-6288, US, LAKSHMANAN, Mark Chandrakant, c/o Eli Lilly and Company P.O. Box 6288
Indianapolis, Indiana 46206-6288, US, TUTTLE, Katherine Rose, c/o Eli Lilly and Company P.O. Box 6288
Indianapolis, Indiana 46206-6288, US, ZIMMERMANN, Alan George, c/o Eli Lilly and Company P.O. Box 6288
Indianapolis, Indiana 46206-6288, US | Representative | Zacco Denmark A/S, Arne Jacobsens Allé 15, 2300 København S | Opponent | | IPC Class | A61K 38/26 (2006.01) , A61K 38/28 (2006.01) , A61K 45/06 (2006.01) , A61P 13/12 (2006.01) , G01N 33/68 (2006.01) | Title | Dulaglutid til behandling af kronisk nyresygdom | Int. application no. | US2018034278 | Int. publication no. | WO2018222472 | Related patent (certificate) | | Status | Rettet DK/EP patent | Pædiatrisk forlængelse | - | Udløbsdato for pædiatrisk forlængelse | - |
|